Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Zhu, Xinmei ^a,b   Nishimura, Fumihiko ^a,b   Sasaki, Kotaro ^a   Fujita, Mitsugu ^a,b   Dusak, Jill E ^a,b   Eguchi, Junichi ^a,b   Fellows Mayle, Wendy ^a   Storkus, Walter J ^a   Walker, Paul R ^c   Salazar, Andres M ^d   Okada, Hideho ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Oncovir Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; EPHRIN RECEPTOR A2; EPITOPE; GAMMA INTERFERON; MONOCLONAL ANTIBODY; OVALBUMIN; TOLL LIKE RECEPTOR 3; TUMOR ANTIGEN; VERY LATE ACTIVATION ANTIGEN 4; CARBOXYMETHYLCELLULOSE; DRUG DERIVATIVE; EPHRIN A2; LIGAND; PEPTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CANCER INFILTRATION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GLIOMA; IMMUNE RESPONSE; LYMPHOCYTE HOMING; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; TREATMENT OUTCOME; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; STAINING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; UPREGULATION; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARBOXYMETHYLCELLULOSE SODIUM; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPHRIN-A2; EPITOPES; GLIOMA; HUMANS; INJECTIONS, INTRAMUSCULAR; INTEGRIN ALPHA4BETA1; LIGANDS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDES; POLY I-C; POLYLYSINE; STAINING AND LABELING; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 3; TREATMENT OUTCOME; UP-REGULATION; VACCINATION;

EID: 33847674371     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-10     Document Type: Article

References (50)

1. Nishimura F Dusak JE Eguchi J Zhu X Gambotto A Storkus WJ Okada H Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: Critical roles of IFN-inducible protein-10. Cancer Res 2006 66 4478-4487 10.1158/0008-5472.CAN-05-3825 16618775
2. Wang T Town T Alexopoulou L Anderson JF Fikrig E Flavell RA Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis Nat Med 2004 10 1366-1373 10.1038/nm1140 15558055
3. Farina C Krumbholz M Giese T Hartmann G Aloisi F Meinl E Preferential expression and function of Toll-like receptor 3 in human astrocytes J Neuroimmunol 2005 159 12-19 10.1016/j.jneuroim.2004.09.009 15652398.
4. Salazar AM Levy HB Ondra S Kende M Scherokman B Brown D Mena H Martin N Schwab K Donovan D Dougherty D Pulliam M Ippolito M Graves M Brown H Ommaya A Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: An open pilot study Neurosurgery 1996 38 1096-1103 10.1097/00006123-199606000-00006 8727138.
5. Michelsen KS Doherty TM Shah PK Arditi M TLR signaling: An emerging bridge from innate immunity to atherogenesis J Immunol 2004 173 5901-5907 15528321
6. Ku CL Yang K Bustamante J Puel A Von BH Santos OF Lawrence T Chang HH Al-Mousa H Picard C Casanova JL Inherited disorders of human Toll-like receptor signaling: Immunological implications Immunol Rev 2005 203 10-20 10.1111/j.0105-2896.2005.00235.x 15661018
7. Alexopoulou L Holt AC Medzhitov R Flavell RA Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 Nature 2001 413 732-738 10.1038/35099560 11607032
8. Edelmann KH Richardson-Burns S Alexopoulou L Tyler KL Flavell RA Oldstone MBA Does Toll-like receptor 3 play a biological role in virus infections? Virology 2004 322 231-238 10.1016/j.virol.2004.01.033 15110521
9. Tabeta K Georgel P Janssen E Du X Hoebe K Crozat K Mudd S Shamel L Sovath S Goode J Alexopoulou L Flavell RA Beutler B Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection Proc Natl Acad Sci U S A 2004 101 3516-3521 373494 14993594 10.1073/pnas.0400525101
10. Mailliard RB Wankowicz-Kalinska A Cai Q Wesa A Hilkens CM Kapsenberg ML Kirkwood JM Storkus WJ Kalinski P alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity Cancer Res 2004 64 5934-5937 10.1158/0008-5472.CAN-04-1261 15342370
11. Salem ML El-Naggar SA Kadima A Gillanders WE Cole DJ The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu Vaccine 2006 24 5119-5132 10.1016/j.vaccine.2006.04.010 16704888
12. Salem ML Kadima AN Cole DJ Gillanders WE Defining the antigen-specific T-cell respoEse to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity J Immunother 2005 28 220-228 10.1097/01.cji.0000156828.75196.0d 15838378
13. Olson JK Miller SD Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs J Immunol 2004 173 3916-3924 15356140
14. Jack CS Arbour N Manusow J Montgrain V Blain M McCrea E Shapiro A Antel JP TLR signaling tailors innate immune responses in human microglia and astrocytes J Immunol 2005 175 4320-4330 16177072
15. Park C Lee S Cho IH Lee HK Kim D Choi SY Oh SB Park K Kim JS Lee SJ TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: Differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression GLIA 2006 53 248-256 10.1002/ glia.20278 16265667
16. Fazakerley JK Innate and Adaptive Immune Responses in Viral Encephalitis Centr 2005
17. Laschinger M Engelhardt B Interaction of alpha4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro J Neuroimmunol 2000 102 32-43 10.1016/S0165-5728(99)00156-3 10626664
18. Engelhardt B Laschinger M Schulz M Samulowitz U Vestweber D Hoch G The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin J Clin Invest 1998 102 2096-2105 509164 9854045
19. Calzascia T Masson F Di Berardino-Besson W Contassot E Wilmotte R urrand-Lions M Ruegg C Dietrich PY Walker PR Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs Immunity 2005 22 175-184 10.1016/ j.immuni.2004.12.008 15723806
20. Foster GR Masri SH David R Jones M Datta A Lombardi G Runkell L de DC Sizing I James MJ Marelli-Berg FM IFN-alpha subtypes differentially affect human T cell motility J Immunol 2004 173 1663-1670 15265895
21. Kuwashima N Nishimura F Eguchi J Sato H Hatano M Tsugawa T Sakaida T Dusak JE Fellows-Mayle WK Papworth GD Watkins SC Gambotto A Pollack IF Storkus WJ Okada H Delivery of Dendritic Cells Engineered to Secrete IFN-{alpha} into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways J Immunol 2005 175 2730-2740 16081851
22. Okada H Tsugawa T Sato H Kuwashima N Gambotto A Okada K Dusak JE Fellows-Mayle WK Papworth GD Watkins SC Chambers WH Potter DM Storkus WJ Pollack IF Delivery of Interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines Cancer Res 2004 64 5830-5838 10.1158/ 0008-5472.CAN-04-0130 15313927
23. Eguchi J Hatano M Nishimura F Zhu X Dusak JE Sato H Pollack IF Storkus WJ Okada H Identification of interleukin-13 receptor 2 peptide analogues capable of inducing improved anti-glioma CTL responses. Cancer Res 2006 66 5883-5891 10.1158/0008-5472.CAN-06-0363 16740728
24. Walker PR Calzascia T Schnuriger V Scamuffa N Saas De Tribolet N Dietrich PY The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells J Immunol 2000 165 3128-3135 10975826
25. Coles RM Mueller SN Heath WR Carbone FR Brooks AG Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 2002 168 834-838 11777979
26. Prins RM Odesa SK Liau LM Immunotherapeutic Targeting of Shared Melanoma-Associated Antigens in a Murine Glioma Model Cancer Res 2003 63 8487-8491 14679014
27. Hatano M Eguchi J Tatsumi T Kuwashima N Dusak JE Kinch MS Pollack IF Hamilton RL Storkus WJ Okada H EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines Neoplasia 2005 7 717-722 1501889 16207473 10.1593/neo.05277
28. Hatano M Kuwashima N Tatsumi T Dusak JE Nishimura F Reilly KM Storkus WJ Okada H Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors J Transl Med 2004 2 40 535538 15563374 10.1186/1479-5876-2-40
29. Janeway CAJ Travers P Immunobiology Current Biology Ltd. Garland Publishing Inc. 2 1996
30. Kluver H Barrera E A method for the combined staining of cells and fibers in the nervous system J Neuropathol Exp Neurol 1953 12 400-403 13097193
31. Luft T Pang KC Thomas E Hertzog P Hart DN Trapani Cebon J Type I IFNs enhance the terminal differentiation of dendritic cells J Immunol 1998 161 1947-1953 9712065
32. Montoya M Schiavoni G Mattei F Gresser I Belardelli F Borrow P Tough DF Type I interferons produced by dendritic cells promote their phenotypic and functional activation Blood 2002 99 3263-3271 10.1182/ blood.V99.9.3263 11964292
33. Le Bon A Etchart N Rossmann C Ashton M Hou S Gewert D Borrow P Tough DF Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon Nat Immunol 2003 4 1009-1015 10.1038/ni978 14502286
34. Marrack P Kappler J Mitchell T Type I interferons keep activated T cells alive J Exp Med 1999 189 521-530 10.1084/jem.189.3.521 9927514
35. Hiroishi K Tuting T Lotze MT IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs J Immunol 2000 164 567-572 10623796
36. Durand V Wong SY Tough DF Le BA Shaping of adaptive immune responses to soluble proteins by TLR agonists: A role for IFN-alpha/beta Immunol Cell Biol 2004 82 596-602 10.1111/j.0818-9641.2004.01285.x 15550117
37. Rice GP Hartung HP Calabresi PA Anti-alpha4 integrin therapy for multiple sclerosis: Mechanisms and rationale Neurology 2005 64 1336-1342 15851719
38. Wirth S van den BM Frossard CP Hugin AW Leblond I Pircher H Hauser C CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection Cell Immunol 2000 202 13-22 10.1006/ cimm.2000.1639 10873302
39. Schmidt KN Leung B Kwong M Zarember KA Satyal S Navas TA Wang F Godowski PJ APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA J Immunol 2004 172 138-143 14688319
40. Sivori S Falco M Della CM Carlomagno S Vitale M Moretta L Moretta A CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells Proc Natl Acad Sci U S A 2004 101 10116-10121 454174 15218108 10.1073/pnas.0403744101
41. Pisegna S Pirozzi G Piccoli M Frati L Santoni A Palmieri G p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells Blood 2004 104 4157-4164 10.1182/ blood-2004-05-1860 15315972
42. Mailliard RB Son YI Redlinger R Coates PT Giermasz A Morel PA Storkus WJ Kalinski P Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function J Immunol 2003 171 2366-2373 12928383
43. Gerosa F Gobbi A Zorzi P Burg S Briere F Carra G Trinchieri G The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions J Immunol 2005 174 727-734 15634892
44. Carter LL Dutton RW Type 1 and type 2: A fundamental dichotomy for all T-cell subsets Curr Opin Immunol 1996 8 336-342 10.1016/ S0952-7915(96)80122-1 8793995
45. Sad S Marcotte R Mosmann TR Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines Immunity 1995 2 271-279 10.1016/1074-7613(95)90051-9 7697544
46. Dudley ME Wunderlich JR Yang JC Sherry RM Topalian SL Restifo NP Royal RE Kammula U White DE Mavroukakis SA Rogers LJ Gracia GJ Jones SA Mangiameli DP Pelletier MM Gea-Banacloche J Robinson MR Berman DM Filie AC Abati A Rosenberg SA Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 2005 23 2346-2357 1475951 15800326 10.1200/JCO.2005.00.240
47. Lang KS Recher M Junt T Navarini AA Harris NL Freigang S Odermatt B Conrad C Ittner LM Bauer S Luther SA Uematsu S Akira S Hengartner H Zinkernagel RM Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease Nat Med 2005 11 138-145 10.1038/nm1176 15654326
48. Riker A Cormier J Panelli M Kammula U Wang E Abati A Fetsch P Lee KH Steinberg S Rosenberg S Marincola F Immune selection after antigen-specific immunotherapy of melanoma Surgery 1999 126 112-120 10455872
49. Scanlan MJ Simpson AJ Old LJ The cancer/testis genes: Review, standardization, and commentary Cancer Immun 2004 4 1 14738373
50. Barth RF Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. [Review] [152 refs] J Neuro Oncol 1998 36 91-102 10.1023/A:1005805203044